HOPE Therapeutics, a wholly-owned subsidiary of NRx Pharmaceuticals (NRXP), announced the planned acquisition of the Kadima Neuropsychiatry Institute of La Jolla, CA, per the previously announced Letter of Intent, for the HOPE network. Kadima is expected to serve as the flagship clinic for HOPE’s planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD. Upon consummation of the proposed acquisition, Kadima’s founder and CEO, Prof. David Feifel, MD PHD, will serve as HOPE’s Chief Medical Innovation Officer, focused on identifying and evaluating new developments in the treatment of CNS disorders. The acquisition of Kadima is subject to the completion of financial audits, execution of definitive agreements, the satisfaction of standard closing conditions.
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRXP:
- NRx Pharmaceuticals announces first section of NDA for NRX-100
- NRX Pharmaceuticals Strengthens Leadership with New CFO Appointment
- NRx Pharmaceuticals Reports Progress in Drug Development
- NRx Pharmaceuticals names Michael Abrams as CFO
- NRX Pharmaceuticals Advances in Mental Health Sector
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
